Australia's most trusted
source of pharma news
Posted 19 August 2025 PM
CSL has outlined plans to streamline the company, by cutting 15 per cent of its non-plasma centre workforce, amounting to 3,000 jobs globally, and spinning off CSL Seqirus into a separate ASX-listed company.
CEO Paul McKenzie told the FY25 earnings call this morning that demerging Seqirus would enable both companies to "focus on their core capabilities and realise simplification benefits which will drive growth, and each will have a sustainable capital structure and access to funding to pursue distinct growth opportunities."
Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.
Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.